Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Current Investments (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cash & Current Investments for 10 consecutive years, with $128.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 85.05% year-over-year to $128.6 million, compared with a TTM value of $199.5 million through Sep 2025, up 123.22%, and an annual FY2025 reading of $128.6 million, up 85.05% over the prior year.
  • Cash & Current Investments was $128.6 million for Q4 2025 at Zevra Therapeutics, down from $199.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $202.6 million in Q2 2025 and bottomed at $43.3 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $95.4 million, with a median of $76.8 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments soared 3122.28% in 2021, then plummeted 46.72% in 2022.
  • Year by year, Cash & Current Investments stood at $112.3 million in 2021, then fell by 26.69% to $82.4 million in 2022, then decreased by 17.76% to $67.7 million in 2023, then grew by 2.6% to $69.5 million in 2024, then skyrocketed by 85.05% to $128.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for ZVRA at $128.6 million in Q4 2025, $199.5 million in Q3 2025, and $202.6 million in Q2 2025.